Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer

F. Poumeaud,M. Morisseau,L. Cabel,A. Gonçalves,C. Rivier,O. Trédan,E. Volant,J.-S. Frenel,S. Ladoire,W. Jacot,M. Jamelot,H. Foka Tichoue,A. Patsouris,L. Teixeira,F.-C. Bidard,D. Loirat,M. Brunet,C. Levy,C. Bailleux,B. Cabarrou,A. Deleuze,L. Uwer,E. Deluche,T. Grellety,C. Franchet,F. Fiteni,H. Bischoff,R. Vion,M. Pagliuca,B. Verret,S. Bécourt,T. Reverdy,A. de Nonneville,F. Dalenc

DOI: https://doi.org/10.1038/s41416-024-02766-9

IF: 9.075

2024-06-26

British Journal of Cancer

Abstract:Current guidelines recommend that patients with HER2-low metastatic breast cancer (MBC) receive sequentially two antibody–drug conjugates (ADCs): Sacituzumab Govitecan (SG) and Trastuzumab Deruxtecan (T-DXd), despite a similar payload. However, the effectiveness of one after another is unknown.

oncology